Changes of the Bone Metabolism Markers and Body Composition in Nonalcoholic Fatty Liver Disease by the SGLT2 inhibitor

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 782-P
Author(s):  
CHIZURU WATANABE ◽  
NORIO AKUTA ◽  
YOSHIYUKI SUZUKI ◽  
MASAHIRO KOBAYASHI ◽  
YASUMICHI MORI ◽  
...  
Keyword(s):  
Body Composition ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Bone Metabolism ◽  
Fatty Liver Disease ◽  
Sglt2 Inhibitor ◽  
Bone Metabolism Markers ◽  
Nonalcoholic Fatty Liver

scholarly journals Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis

2019 ◽  
Vol 3 (8) ◽  
pp. 1073-1084 ◽  
Author(s):  
Vincent L. Chen ◽  
Andrew P. Wright ◽  
Brian Halligan ◽  
Yanhua Chen ◽  
Xiaomeng Du ◽  
...  
Keyword(s):  
Body Composition ◽  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Risk Score ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver

scholarly journals Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Fangli Zhou ◽  
Yan Wang ◽  
Yujue Li ◽  
Mengjia Tang ◽  
Shan Wan ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Bone Metabolism ◽  
High Fat Diet ◽  
Fatty Liver Disease ◽  
Metabolic Parameters ◽  
High Fat ◽  
Nonalcoholic Fatty Liver ◽  
Control Subjects

ObjectivesGrowing evidence argues for a relationship between liver and bone metabolisms. Sclerostin is a secreted glycoprotein and could antagonize osteoblast-mediated bone formation. Previous studies indicated that circulating sclerostin levels may be associated with metabolic parameters with inconsistent results. This study was designed to evaluate serum sclerostin in patients with or without nonalcoholic fatty liver disease (NAFLD) and to analyze its relationship with metabolic parameters in different populations.MethodsA cross-sectional study was designed and 168 NAFLD subjects and 85 control subjects were included in this study. Serum sclerostin and metabolic parameters were measured. Mouse models of NAFLD were also induced by high-fat diet. Bone structural parameters were determined using microCT and mRNA expression levels of sclerostin in bone and liver tissues were measured.ResultsOur study suggested that circulating sclerostin levels were significantly lower in NAFLD subjects compared with normal controls. In NAFLD subjects, sclerostin was negatively correlated with multiple metabolic parameters, including waist circumference, urea, hepatic enzyme, gamma-glutamyl transpeptidase, and triglyceride, while such correlation was not significant in control subjects. Circulating sclerostin was also negatively correlated with fatty liver index in NAFLD subjects but not in control subjects. Mice fed on a high-fat diet had reduced bone mass and lower sclerostin expression levels in both the bone and liver tissues.ConclusionsOur study suggested that the liver-lipid-bone interactions may play a key role in the abnormal bone metabolism in NAFLD, and circulating sclerostin may be a surrogate marker to reflect bone metabolism status in NAFLD subjects.

scholarly journals Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma

2015 ◽  
Vol 173 (3) ◽  
pp. 389-397 ◽  
Author(s):  
Anika Hoffmann ◽  
Klaus Bootsveld ◽  
Ursel Gebhardt ◽  
Anna M M Daubenbüchel ◽  
Anthe S Sterkenburg ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Composition ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Model Assessment ◽  
Childhood Onset ◽  
Nonalcoholic Fatty Liver ◽  
Elevated Liver Enzymes

ObjectiveHypothalamic obesity in childhood craniopharyngioma (CP) patients carries a high risk for development of metabolic syndrome. In metabolic syndrome, the development of nonalcoholic fatty liver disease (NAFLD) is known. The aim of this study is to detect the risk for NAFLD in childhood-onset CP.DesignThis cross-sectional study included liver computed tomography (CT); ultrasound analysis of abdomen; measurements of serum parameters, height, weight and body composition; and daily medication of patients with childhood-onset CP.MethodsA total of 384 patients recruited in trials HIT Endo and KRANIOPHARYNGEOM 2000 were analyzed. Ninety-four survivors were included by fulfilling the criteria of proven hypothalamic involvement (HI), a minimum time interval of 5 years between diagnosis and study, and a minimum age of 18 years at the time of evaluation. A total of 19 patients agreed to participate. To quantify the degree of steatosis hepatis, analyses of liver density were performed once by non-contrasted CT of liver sections.ResultsNAFLD occurs in about 50% of CP patients with HI and is associated with elevated liver enzymes and homeostasis model assessment index. BMI is not an effective predictive factor but body fat mass measured by near-infrared spectroscopy (NIRS) is. Over half of CP patients (60%) with NAFLD are treated with stimulating agents, with risk of hepatic side effects.ConclusionsNAFLD is a major adverse late effect in childhood-onset CP. NIRS rather than BMI should be used to measure body composition and predict NAFLD. Stimulating agents for treatment of fatigue and daytime sleepiness in CP should be prescribed judiciously.

scholarly journals P-28 BODY COMPOSITION MEASUREMENT AND NONALCOHOLIC FATTY LIVER DISEASE

2021 ◽  
Vol 24 ◽  
pp. 100392
Author(s):  
Maria Auxiliadora Nogueira Saad ◽  
Débora Vieira Soares ◽  
Priscila Pollo Flores ◽  
Rosa Leonora Salerno Soares ◽  
Vinicius César Jardim Pereira ◽  
...  
Keyword(s):  
Body Composition ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Body Composition Measurement ◽  
Composition Measurement

scholarly journals Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease

2020 ◽  
Vol 2 (S1) ◽  
pp. 17-25
Author(s):  
Sumida Y ◽  
Yoneda M ◽  
Tokushige K ◽  
Kawanaka M ◽  
Fujii H ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Cardiovascular Events ◽  
Sglt2 Inhibitor ◽  
Sglt2 Inhibitors ◽  
Nonalcoholic Fatty Liver

A fourth of the adult population is now suffering from nonalcoholic fatty liver disease (NAFLD) worldwide. Nonalcoholic steatohepatitis (NASH), a severe form of NAFLD, can lead to liver-related mortality. NAFLD/NASH is closely associated with type 2 diabetes. Although pioglitazone is now recommended as the 1st line therapy for NASH with type 2 diabetes, pioglitazone has several safety concerns such as body weight gain, heart failure, fluid retention, and bone fracture in women. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have a variety of functions such as glycemic control, bodyweight reduction, and decreased body pressure. Accumulating evidence has shown that this agent has also cardioprotective and renoprotective effects in patients with or without type 2 diabetes. Recent studies that SGLT2 inhibitor can also reduce in transaminase activities or hepatic fat content in NAFLD. NAFLD patients with type 2 diabetes can be indicated for SGLT2 inhibitor, because they are obese, have insulin resistance, and at high risk of cardiovascular events. The phase 3 study of dapagliflozin for NAFLD (DEAN study) is now ongoing. It remains unknown whether this agent can ameliorate hepatic fibrosis in NASH, leading to improved over-all or liver-related survival. Since the leading cause of NAFLD mortality is cardiovascular events, SGLT2 inhibitors will become the 1st line treatment for NAFLD/NASH.

Sign in / Sign up

Export Citation Format

Share Document